Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Firestone RS, Socci ND, Shekarkhand T, Zhu M, Ge Qin W, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt SA, Murata K, Usmani SZ, Chung DJ. Firestone RS, et al. Among authors: tan cr. Blood. 2024 May 10:blood.2023023557. doi: 10.1182/blood.2023023557. Online ahead of print. Blood. 2024. PMID: 38728378
Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz ML, Mailankody S, Tan CR, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt SA, Usmani SZ, Firestone RS. Howard AJ, et al. Among authors: tan cr. Blood Adv. 2024 Apr 12:bloodadvances.2024012871. doi: 10.1182/bloodadvances.2024012871. Online ahead of print. Blood Adv. 2024. PMID: 38621239
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Hamadeh IS, Shekarkhand T, Rueda CJ, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt SA, Usmani SZ, Tan CR. Hamadeh IS, et al. Among authors: tan cr. Blood Adv. 2024 Apr 10:bloodadvances.2024012724. doi: 10.1182/bloodadvances.2024012724. Online ahead of print. Blood Adv. 2024. PMID: 38598713
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
Lesokhin A, Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung D, Landau H, Lahoud O, Scordo M, Shah G, Hassoun H, Maclachlan K, Korde N, Shah U, Tan CR, Hultcrantz M, Giralt S, Usmani S, Shahid Z, Mailankody S. Lesokhin A, et al. Among authors: tan cr. Res Sq [Preprint]. 2024 Feb 7:rs.3.rs-3911922. doi: 10.21203/rs.3.rs-3911922/v1. Res Sq. 2024. PMID: 38405866 Free PMC article. Preprint.
Single-cell transcriptomics reveals colonic immune perturbations during amyloid-β driven Alzheimer's disease in mice.
Makhijani P, Emani R, Aguirre CG, Mu WC, Rane A, Ng JHY, Valentino TR, Manwaring-Mueller M, Tan CR, Du H, Wu F, Khan S, Wilson KA, Winer S, Wang C, Mortha A, Furman D, Ellerby LM, Rojas OL, Andersen JK, Winer DA. Makhijani P, et al. Among authors: tan cr. bioRxiv [Preprint]. 2024 Jan 30:2024.01.27.573841. doi: 10.1101/2024.01.27.573841. bioRxiv. 2024. PMID: 38352325 Free PMC article. Preprint.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. Firestone RS, et al. Among authors: tan cr. Blood Adv. 2024 Apr 9;8(7):1600-1611. doi: 10.1182/bloodadvances.2023011225. Blood Adv. 2024. PMID: 37878808 Free PMC article.
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F, Usmani SZ. Gordan LN, et al. Among authors: tan cr. Clin Lymphoma Myeloma Leuk. 2024 Jan;24(1):55-63. doi: 10.1016/j.clml.2023.09.003. Epub 2023 Sep 14. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37838502 Free article.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Shah UA, Moshier E, Derkach A, Huang Y, Mailankody S, Tan CR, Maclachlan K, Hultcrantz M, Korde N, Hassoun H, Thibaud S, Sanchez L, Rodriguez C, Richard S, Richter J, Rossi A, Cho HJ, Lesokhin A, Chari A, Usmani SZ, Jagannath S, Parekh S, Gallagher EJ. Shah UA, et al. Among authors: tan cr. Blood Adv. 2024 Jan 9;8(1):236-247. doi: 10.1182/bloodadvances.2023010815. Blood Adv. 2024. PMID: 37772981 Free PMC article.
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud OB, Landau HJ, Chung DJ, Shah GL, Scordo M, Giralt SA, Lesokhin A, Usmani SZ, Landgren O, Korde N. Tan CR, et al. Blood Cancer J. 2023 Jul 25;13(1):112. doi: 10.1038/s41408-023-00882-y. Blood Cancer J. 2023. PMID: 37491332 Free PMC article.
56 results